J Drugs Dermatol. 2020 May 1;19(5):477-482.
Dermatologic adverse events (dAEs) secondary to anticancer treatments reduce patients’ quality of life (QOL) and result in interruptions in anticancer therapy.
Determine if a comprehensive supportive oncodermatology program improves patients’ QOL scoring.
This was a cross-sectional survey of adult cancer patients enrolled in the George Washington University Supportive Oncodermatology Clinic. All patients were above age 18 years and received dermatologic care between May 1, 2017 and November 1, 2019. Fifty-five patents meeting inclusion criteria were invited to complete an online survey with questions adapted from the Dermatology Life Quality Index (DLQI) and Patient Satisfaction Questionnaire (PSQ-18).
Survey initiation rate was 61.8% (34/55) and completion rate 88.2% (30/34). Average QOL score prior to treatment was 6.5 (moderate effect on QOL) and 3.8 (small effect) afterwards (P=0.0005; 95% CI -3.9 to -1.). Average satisfaction score was 4.15 ± 0.7 (satisfied). Impact on treatment adherence earned the lowest score (3.67, neutral to satisfied).
Recall bias Conclusion: Enrollment was significantly associated with improved QOL. Dermatologic care also resulted in overall satisfied patient outcomes, although many patients were unsure if these dermatologic interventions aided in anticancer treatment adherence, highlighting the need for evidence-based management strategies for dAEs. J Drugs Dermatol. 2020;19(5): doi:10.36849/JDD.2020.5040.
癌症治疗相关的皮肤不良反应（dAEs）会降低患者的生活质量（QOL），并导致癌症治疗中断。
确定综合支持性肿瘤皮肤科项目是否能改善患者的 QOL 评分。
这是一项对参加乔治华盛顿大学支持性肿瘤皮肤科诊所的成年癌症患者进行的横断面调查。所有患者年龄均在 18 岁以上，于 2017 年 5 月 1 日至 2019 年 11 月 1 日期间接受过皮肤科护理。符合纳入标准的 55 名患者被邀请完成一项在线调查，调查内容改编自皮肤病生活质量指数（DLQI）和患者满意度问卷（PSQ-18）。
调查启动率为 61.8%（34/55），完成率为 88.2%（30/34）。治疗前的平均 QOL 评分为 6.5（对 QOL 有中度影响），治疗后为 3.8（对 QOL 有较小影响）（P=0.0005；95%CI -3.9 至 -1.）。平均满意度评分为 4.15±0.7（满意）。对治疗依从性的影响得分最低（3.67，中立到满意）。
回忆偏倚。结论：入组与 QOL 的改善显著相关。皮肤科护理也使患者总体满意度较高，尽管许多患者不确定这些皮肤科干预措施是否有助于癌症治疗的依从性，这突出了需要制定基于证据的 dAE 管理策略。J 皮肤病药物学杂志。2020;19(5)：doi：10.36849/JDD.2020.5040.
Zotero 插件